HGFR/MET and ALK inhibitors

2012 ◽  
pp. 72-86
Author(s):  
Eunice L Kwak
Keyword(s):  
Alk Inhibitors

Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors

Neurology ◽  
2019 ◽  
Vol 93 (5) ◽  
pp. 217-219
Author(s):  
Alessia Pellerino ◽  
Lucio Buffoni ◽  
Roberta Rudà ◽  
Riccardo Soffietti
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Spinal Metastases ◽  
Complete Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Inhibitors

scholarly journals Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Petros Christopoulos ◽  
Farastuk Bozorgmehr ◽  
Lena Brückner ◽  
Inn Chung ◽  
Johannes Krisam ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Drug Resistance ◽  
Anaplastic Lymphoma Kinase ◽  
Second Generation ◽  
Search Query ◽  
Alk Inhibitors ◽  
Anaplastic Lymphoma ◽  
Link Type ◽  
Biomarker Analysis ◽  
Nsclc Patients

Abstract Background Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second-generation ALK TKI have demonstrated superiority compared to the first-generation compound crizotinib and are meanwhile standard first-line treatment. However, clinical courses of individual patients vary widely, with secondary development of drug resistance and intracranial progression remaining important problems. While these limitations highlight the need for better disease monitoring and additional therapeutic tools, molecular tumor features are increasingly recognized as crucial determinants of clinical outcome. This trial aims to optimize management of ALK+ NSCLC by analyzing the efficacy of second-generation ALK inhibitors in conjunction with deep longitudinal phenotyping across two treatment lines. Methods/design In this exploratory prospective phase II clinical trial, newly diagnosed ALK+ NSCLC patients will be randomized into two treatment arms, stratified by presence of brain metastases and ECOG performance status: brigatinib (experimental arm) vs. any other approved second-generation ALK TKI. Tumor tissue and blood samples will be collected for biomarker analysis at the beginning and throughout the study period to investigate baseline molecular tumor properties and analyze the development of acquired drug resistance. In addition, participating investigators and patients will have the possibility of fast-track molecular tumor and ctDNA profiling at the time of disease progression using state-of-the-art next-generation sequencing (NGS), in order to support decisions regarding next-line therapy. Discussion Besides supporting therapeutic decisions for enrolled patients, the ABP trial primarily aims to deepen the understanding of the underlying biology and facilitate development of a framework for individualized management of ALK+ NSCLC according to molecular features. Patients with low molecular risk and the perspective of a “chronic disease” will be distinguished from “high-risk” cases, molecular properties of which will be utilized to elaborate improved methods of non-invasive monitoring and novel preclinical models in order to advance therapeutic strategies. Trial registration Clinicaltrials.gov, NCT04318938. Registered March 182,020, https://www.clinicaltrials.gov/ct2/show/NCT04318938 Eudra-CT, 2019–001828-36. Registered September 302,019, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001828-36

scholarly journals P3.02a-027 A Retrospective Analysis of the Efficacy and Safety of ALK Inhibitors in ALK-Positive Lung Cancer Patients

2017 ◽  
Vol 12 (1) ◽  
pp. S1178-S1179
Author(s):  
Kazutoshi Komiya ◽  
Tomomi Nakamura ◽  
Yuki Kurihara ◽  
Haruki Hirakawa ◽  
Hironori Sadamatsu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retrospective Analysis ◽  
Cancer Patients ◽  
Efficacy And Safety ◽  
Alk Inhibitors ◽  
Lung Cancer Patients ◽  
Alk Positive

scholarly journals Genomic and experimental evidence that ALKATI does not predict single agent sensitivity to ALK inhibitors.

iScience ◽  
2021 ◽  
pp. 103343
Author(s):  
Haider Inam ◽  
Ivan Sokirniy ◽  
Yiyun Rao ◽  
Anushka Shah ◽  
Farnaz Naeemikia ◽  
...  
Keyword(s):  
Experimental Evidence ◽  
Single Agent ◽  
Alk Inhibitors

scholarly journals ALK and NSCLC: Targeted therapy with ALK inhibitors

10.3410/m3-21 ◽  
2011 ◽  
Vol 3 ◽  
Author(s):  
Bengt Hallberg ◽  
Ruth H. Palmer
Keyword(s):  
Targeted Therapy ◽  
Alk Inhibitors

scholarly journals Response to comment on “ALK is a therapeutic target for lethal sepsis”

2018 ◽  
Vol 10 (471) ◽  
pp. eaas9817
Author(s):  
Daolin Tang ◽  
Rui Kang
Keyword(s):  
Therapeutic Target ◽  
Inflammatory Activity ◽  
Alk Inhibitors ◽  
Lethal Sepsis ◽  
Anti Inflammatory

ALK inhibitors may exhibit STING-independent anti-inflammatory activity in macrophages and monocytes.

Sign in / Sign up

Export Citation Format

Share Document